Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Positive allosteric modulators of alpha7 nicotinic acetylcholine receptors (nAChRs) have attracted considerable interest as potential tools for the treatment of neurological and psychiatric disorders such as Alzheimer's disease and schizophrenia. However, despite the potential therapeutic usefu...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Young, G, Zwart, R, Walker, A, Sher, E, Millar, N
Μορφή: Journal article
Γλώσσα:English
Έκδοση: 2008
_version_ 1826260940573638656
author Young, G
Zwart, R
Walker, A
Sher, E
Millar, N
author_facet Young, G
Zwart, R
Walker, A
Sher, E
Millar, N
author_sort Young, G
collection OXFORD
description Positive allosteric modulators of alpha7 nicotinic acetylcholine receptors (nAChRs) have attracted considerable interest as potential tools for the treatment of neurological and psychiatric disorders such as Alzheimer's disease and schizophrenia. However, despite the potential therapeutic usefulness of these compounds, little is known about their mechanism of action. Here, we have examined two allosteric potentiators of alpha7 nAChRs (PNU-120596 and LY-2087101). From studies with a series of subunit chimeras, we have identified the transmembrane regions of alpha7 as being critical in facilitating potentiation of agonist-evoked responses. Furthermore, we have identified five transmembrane amino acids that, when mutated, significantly reduce potentiation of alpha7 nAChRs. The amino acids we have identified are located within the alpha-helical transmembrane domains TM1 (S222 and A225), TM2 (M253), and TM4 (F455 and C459). Mutation of either A225 or M253 individually have particularly profound effects, reducing potentiation of EC(20) concentrations of acetylcholine to a tenth of the level seen with wild-type alpha7. Reference to homology models of the alpha7 nAChR, based on the 4A structure of the Torpedo nAChR, indicates that the side chains of all five amino acids point toward an intrasubunit cavity located between the four alpha-helical transmembrane domains. Computer docking simulations predict that the allosteric compounds such as PNU-120596 and LY-2087101 may bind within this intrasubunit cavity, much as neurosteroids and volatile anesthetics are thought to interact with GABA(A) and glycine receptors. Our findings suggest that this is a conserved modulatory allosteric site within neurotransmitter-gated ion channels.
first_indexed 2024-03-06T19:13:43Z
format Journal article
id oxford-uuid:17a56c8e-8b72-47e2-8d50-bb77ccea2ddf
institution University of Oxford
language English
last_indexed 2024-03-06T19:13:43Z
publishDate 2008
record_format dspace
spelling oxford-uuid:17a56c8e-8b72-47e2-8d50-bb77ccea2ddf2022-03-26T10:38:34ZPotentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:17a56c8e-8b72-47e2-8d50-bb77ccea2ddfEnglishSymplectic Elements at Oxford2008Young, GZwart, RWalker, ASher, EMillar, NPositive allosteric modulators of alpha7 nicotinic acetylcholine receptors (nAChRs) have attracted considerable interest as potential tools for the treatment of neurological and psychiatric disorders such as Alzheimer's disease and schizophrenia. However, despite the potential therapeutic usefulness of these compounds, little is known about their mechanism of action. Here, we have examined two allosteric potentiators of alpha7 nAChRs (PNU-120596 and LY-2087101). From studies with a series of subunit chimeras, we have identified the transmembrane regions of alpha7 as being critical in facilitating potentiation of agonist-evoked responses. Furthermore, we have identified five transmembrane amino acids that, when mutated, significantly reduce potentiation of alpha7 nAChRs. The amino acids we have identified are located within the alpha-helical transmembrane domains TM1 (S222 and A225), TM2 (M253), and TM4 (F455 and C459). Mutation of either A225 or M253 individually have particularly profound effects, reducing potentiation of EC(20) concentrations of acetylcholine to a tenth of the level seen with wild-type alpha7. Reference to homology models of the alpha7 nAChR, based on the 4A structure of the Torpedo nAChR, indicates that the side chains of all five amino acids point toward an intrasubunit cavity located between the four alpha-helical transmembrane domains. Computer docking simulations predict that the allosteric compounds such as PNU-120596 and LY-2087101 may bind within this intrasubunit cavity, much as neurosteroids and volatile anesthetics are thought to interact with GABA(A) and glycine receptors. Our findings suggest that this is a conserved modulatory allosteric site within neurotransmitter-gated ion channels.
spellingShingle Young, G
Zwart, R
Walker, A
Sher, E
Millar, N
Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
title Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
title_full Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
title_fullStr Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
title_full_unstemmed Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
title_short Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
title_sort potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site
work_keys_str_mv AT youngg potentiationofalpha7nicotinicacetylcholinereceptorsviaanallosterictransmembranesite
AT zwartr potentiationofalpha7nicotinicacetylcholinereceptorsviaanallosterictransmembranesite
AT walkera potentiationofalpha7nicotinicacetylcholinereceptorsviaanallosterictransmembranesite
AT shere potentiationofalpha7nicotinicacetylcholinereceptorsviaanallosterictransmembranesite
AT millarn potentiationofalpha7nicotinicacetylcholinereceptorsviaanallosterictransmembranesite